Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report (Q33860770)

29 July 2017

1 reference

title

Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report (English)

1 reference

Primary systemic amyloidosis

29 July 2017

1 reference

1 reference

1

Gertz MA

1 reference

29 July 2017

2

Lacy MQ

1 reference

29 July 2017

3

Dispenzieri A

1 reference

PubMed ID

10713619

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

Bone Marrow Transplantation

29 July 2017

1 reference

29 July 2017

25

1 reference

29 July 2017

5

1 reference

29 July 2017

465-470

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1702178

29 July 2017

0 references

cites work

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

Amyloidosis: prognosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

Amyloidosis: a review of recent diagnostic and therapeutic developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Letter: Improvement in amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Allogeneic bone marrow transplantation for systemic AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Allogeneic bone marrow transplantation for AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702178

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1702178

1 reference

PubMed ID

10713619

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

10713619